In B-ALL mouse models, inhibition of catecholamine synthesis by methyltyrosine (MTR) or atrial natriuretic peptide (ANP) resulted in a significant decrease in IL-6 and TNF-α levels and an improvement in survival rate without compromising the efficacy of CD19 CAR-T cells [78]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.